ArticleBMC medical research methodology2026
The predictive power of first recruits to commercial trial performance.
Article in BMC medical research methodology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe United Kingdom has a history of world-leading health research, showcased most recently in its response to the Covid pandemic. However, while the UK's performance in academic clinical research remains strong, its global position in the delivery of commercial research has declined. In 2023 Lord O'Shaughnessy reviewed the barriers and drivers to the delivery of commercial trials, identifying 27 recommendations to improve commercial trial performance. Highlighted within the report was the importance of the UK being globally competitive in the delivery of its trials, including study set up and approval times.
methodsA dataset from the National Institute for Health and Care Research (NIHR), containing 28,188 site observations from 5,421 unique commercial studies provided data on first recruits to commercial studies spanning a 15-year period from 2010 to 2024. Where there were issues with data quality or reliability, data were cleaned, leaving 23,622 observations from 4,849 studies for analysis. Logistic regression and generalised linear mixed effects models were applied to determine whether sites that recruited their first participant to commercial studies more quickly had a higher probability of recruiting to time and target.
resultsSites that recruited their first participant more quickly were significantly more likely to recruit to time and target (RTT); (odds ratio per one-month increase in time 0.88, 95% CI 0.87 to 0.89, p < 0.0001). The model suggests that the predicted probability of RTT for a site falls to < 50% if it takes more than 8 months to recruit its first participant. A secondary analysis showed a highly significant increase in probability of a site meeting RTT if they recruited the 'first' Global, European or UK participants onto a study (odds ratio 2.96, 95% CI 2.20 to 4.05, p < 0.0001).
conclusionsSites that recruit first participants more quickly are more likely to recruit to time and target in commercial studies. This is likely to lead to them being selected by sponsors to participate in subsequent studies, increasing research opportunities for their patients and revenue for their organisation. Achieving quicker firsts requires proactive planning and coordination by R&D departments and study teams. Setting up sites in a timely manner is a key determinant of successful study delivery and a key component of the UK government's 10-Year Health Plan for England and Life Sciences Sector Plan.
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.